The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Prioritizing scalability early on is key to successful drug development: Expert insight series
Go inside Accelerator™ Drug Development to discover the key drivers of success in the early phases of drug development and why building a robust, scalable strategy from the outset is essential to long-term program success.
In the early stages of drug development, biotech and pharma companies are often focused on achieving the next milestone on their journey to market. But according to Paul Jorjorian, VP of Development and Scientific Solutions, Drug Substance, Pharma Services, Thermo Fisher Scientific, the decisions made early can have a lasting impact on a program's long-term success. That's why it's critical for drug developers to start with the end in mind.
How to build a scalable drug development strategy early on
In this video—the first in a seven-part expert-led series—Paul explores the key drivers of success in early drug development and explains how biotech and pharma companies can build a robust, scalable strategy that evolves alongside their programs as they progress through process development, analytical method transfer, technology transfer, scale-up, clinical manufacturing, supply chain management, and commercialization.
Drawing on decades of industry experience, Paul also shares the common pitfalls he's seen biotech and pharma companies encounter—and how to avoid them. From underestimating the complexity of technology transfer to overlooking the importance of cross-functional collaboration and the time-intensive nature of vendor management, he explains why thoughtful decisions made early can de-risk development and keep biopharma programs on track.
Key early drug development insights you’ll gain from this video:
- Why technology transfer is often more complex than drug developers expect
- How decisions made in the early stages can create downstream challenges
- Why success requires early, holistic planning—not just a focus on what’s next
- How cross-functional collaboration reduces risk and accelerates development
- How Accelerator™ Drug Development helps support strategic decision-making
Expert:
Paul Jorjorian, VP of Development and Scientific Solutions, Drug Substance, Pharma Services, Thermo Fisher Scientific
Paul Jorjorian is Vice President, Development & Scientific Solutions at Thermo Fisher Scientific, bringing deep technical and operational expertise across biologics, mRNA, viral vectors, and small-molecule APIs. His background spans process and analytical method development, manufacturing, technology transfer, scale-up, and CMC strategy. He leads scientific and technology strategies that connect development with manufacturing execution, accelerating technology transfer, strengthening analytical readiness, and advancing innovative, scalable solutions. His work combines scientific rigor with manufacturing experience to solve complex customer challenges and enable reliable progression from early development through clinical and commercial manufacturing.
This is part of a larger series, “Expert Perspective: Inside Accelerator™ Drug Development.” Watch the full video featuring seven industry-leading, cross-functional experts here.